MKI67 and neuroendocrine carcinoma: The NET-001 study was a prospective phase II trial of avelumab in 10participants, including 9 with EP-PD-NEC and 1 with SCLC, who had all received 1or 2 previous lines of systemic therapy (Table 4).76 The median Ki-67 indexwas 82.5%.76 Median PFS and OS were 2.0 months and 5.7 months,respectively, and a single participant experienced disease control.76 Thesedisappointing outcomes do not support the use of avelumab monotherapy inpatients with advanced high-grade NECs and unfortunately, data relating totranslational endpoints, including PD-L1 positivity, MSI status and TMB were notincluded.